Dose Insider / Analyses / Zepbound plateau

Zepbound PlateauWhen Weight Loss Slows, Why, and What the Trials Show

Updated November 20, 2026 · 24 min read · SURMOUNT-1 analysis, FDA label

A plateau on Zepbound is the expected course, not a breakdown. In the main trial, about half of the people had reached theirs by week 24 and 88 in 100 by week 60.

Week 24by then about half of the trial’s participants had plateaued
When weight loss levelled offAnalysis of the main Zepbound trial, share of participantsBy week 2449%Weeks 36 to 6039%Not by week 7212%When weight loss levelledoffAnalysis of the main Zepbound trial, share ofparticipantsBy week 2449%Weeks 36 to 6039%Not by week 7212%

Those whose loss levelled off by week 24 had lost 12.1% by then and 15.4% by week 72.

On this page

The analysis counted a plateau as soon as the weight changed by less than 5% over 12 weeks, so many people "on a plateau" were still losing, only slowly.

This page lets you check your own last 12 weeks against that definition. Then it goes through when the plateau comes, how the pace falls on each dose, why it happens, where the weight settles, and what is and is not known about a higher dose, diet and exercise at that point.

Is this a plateau by the trial's definition?

Enter your weight before Zepbound, your weight 12 weeks ago and your weight now. The calculator compares the last 12 weeks with the rule the trial analysis used, and puts you on the trial's average curve.

Plateau checkSURMOUNT-1
Unit
Your dose
Last 12 weeks—
Since the start—
Trial average for your doseYour last 12 weeks

Log your weight each week in the app and it keeps the 12-week change for you.

Open the app

The numbers along the bottom are weeks of treatment, and the scale on the left is percent of starting weight. The curve is the trial average and ends at week 72, the last visit. "Slow phase", "flat" and "drifting up" are our labels inside the trial's 5% band.

The rule comes from an analysis of the main Zepbound trial, SURMOUNT-1, published in 2025. Its authors defined a weight plateau as "a weight change <5% over a 12-week interval and all subsequent 12-week intervals", and counted the time to plateau from the first dose to the start of the first such interval.1

Two things about that rule are easy to miss. It looks at 12 weeks, not at one or two. A fortnight without movement on the scale does not come close to it. And its threshold is wide. Five percent of body weight in 12 weeks is a real amount of weight, as the table shows.

Weight at the start of the 12 weeks5% of it lbPer week lb
180 lb9.00.75
200 lb10.00.83
220 lb11.00.92
250 lb12.51.04
300 lb15.01.25

Our arithmetic. Anything slower than the last column, held for 12 weeks, falls inside the trial's definition.

Someone at 220 lb who loses 8 lb in 12 weeks is on a plateau in the language of the trial. Most people would call that steady progress. This is why the calculator separates a slow phase, in which the weight is still falling, from a flat one, and why the word "plateau" in a headline about the trial means less than it sounds.

Slow is not stopped

The analysis shows this in its own numbers. The people who reached their plateau earliest, by week 24, had lost 12.1% of their weight at that point. By week 72 the same people were down 15.4%.1 They lost another 3.3 points of their starting weight in the 48 weeks after the plateau began. For someone who started at 230 lb, that is about 8 lb more.

The calculator opens with a person close to the trial average: 231 lb before treatment, 187 lb at week 36 on 15 mg, and 3 lb lost in the last 12 weeks. That is 1.6% in 12 weeks, well inside the definition, on a total loss of 19%.

Three examples

Week 24 on 10 mg. 240 lb before treatment, 212 lb twelve weeks ago, 199 lb now. The last 12 weeks took off 13 lb, which is 6.1% of 212. That is above 5%, so this is not a plateau. The total loss is 17.1%.

Week 40 on 15 mg. 260 lb before, 212 lb twelve weeks ago, 206 lb now. Six pounds in 12 weeks is 2.8%. By the trial's rule the plateau has begun, and the weight is still coming down at half a pound a week. The total loss is 20.8%.

Week 64 on 15 mg. 220 lb before, 172 lb twelve weeks ago, 171 lb now. One pound in 12 weeks is 0.6%: flat. The total loss is 22.3%, almost exactly the trial average for that dose at that point.

The three people are at different stages of the same course. Only the third has a weight that has stopped, and that person has lost more than a fifth of their starting weight.

When does the plateau come?

For most people between week 24 and week 60. The analysis covered 1,438 participants who took their injections as assigned and had lost at least 5% by the end of the trial. It sorted them by the week in which their plateau began.1

When people plateauedSURMOUNT-1
Plateau began

Each dot is one person in a hundred. 702, 567 and 169 of 1,438 participants. Weights were compared every 12 weeks, so a plateau could begin at week 24, 36, 48 or 60.

Plateau beganPeopleShareLoss when it beganLoss at week 72
By week 2470249%12.1%15.4%
Weeks 36 to 6056739%24.3%26.3%
Not by week 7216912%—25.9%

Horn and colleagues, Clinical Obesity 2025, SURMOUNT-1.

The table carries the main point of the whole analysis. The earlier the plateau began, the smaller the loss it began at. People whose weight slowed by week 24 had lost about 12%. People whose weight kept moving past week 36 had lost about 24% before it slowed, twice as much. And about one person in eight had not settled under 5% per 12 weeks when the trial ended.

The authors drew a practical conclusion from this: the loss at the point of plateau "could be used to predict longer-term weight reduction from treatment and support decisions to modify treatment if necessary".1 In other words, where you are when the pace drops is a fair guide to where you will end up on the same dose.

By starting BMI

The analysis also split people by their body mass index before treatment. In the first 24 weeks the four groups lost almost the same share of their weight. After week 24 they parted: the heavier the starting BMI, the more was still to come.

BMI before treatmentMedian week of plateauLoss, weeks 0 to 24Further loss, weeks 24 to 72Plateau reached by week 72
27 to under 3024.313.4%4.6%90.2%
30 to under 3526.014.5%7.0%88.9%
35 to under 4036.114.3%8.8%87.6%
40 and over36.113.3%9.7%87.8%

A person who starts with a BMI of 28 and a person who starts at 42 lose at the same rate for six months. Then the first slows at about week 24 and the second keeps going to about week 36, adding roughly twice as much in the later part of the trial. An early plateau at a lower starting weight is the pattern the trial found, not a sign that something went wrong.

The paper gives the same contrast in BMI points. After week 24, people in the lowest group lost 1 BMI point or less on average, while people who started with a BMI of 40 or more lost a further 3.7 points. A second trial analysed in the same paper, with 259 participants, showed the same pattern, and there the highest group lost 6 points after week 24.1

How fast does the pace fall?

The label's chart of the trial gives the average weight at each visit. Cutting that curve into 12-week blocks shows how much of their body weight people lost in each block, and when the average itself dropped under 5%.2

The pace in 12-week blocksLabel Fig. 3
Dose
5% or moreUnder 5%

Each bar is the average loss in that block as a share of the weight at its start. Values read from Figure 3 of the label, which shows people while on treatment.

Average loss from the start5 mg10 mg15 mg
Week 127.9%8.6%8.6%
Week 2411.6%14.3%14.6%
Week 3613.7%17.4%18.1%
Week 4815.0%19.1%20.2%
Week 6016.0%20.6%21.6%
Week 7216.1%20.9%22.0%

Zepbound label, Figure 3, Study 1.

The first 12 weeks are the fastest on every dose, at about 8% of body weight. On 5 mg the average already falls under 5% in the second block, weeks 13 to 24. On 10 and 15 mg it holds above 5% for one block longer and falls under it in weeks 25 to 36. By the last block the average loss is half a percent or less on all three.

So on the average curve the 12-week loss was under 5% from week 12 on 5 mg and from week 24 on the higher doses. In the analysis itself the earliest plateau group begins at week 24, the first visit after the dose step-up. The weight loss chart shows the same curve week by week in your own weight.

How much is still ahead at each point

The same curve can be read forwards: from any week, how much more did the average participant lose by the end of the trial?

Still to come by week 72, in points of starting weight5 mg10 mg15 mg15 mg, for a 231 lb start lb
From week 128.212.313.431
From week 244.56.67.417
From week 362.43.53.99
From week 481.11.81.84
From week 600.10.30.41

Our subtraction from the label's Figure 3. Averages, for people who stayed on treatment.

At week 24, the most common week for a plateau to begin, the average participant on 15 mg still had 7.4 points to lose, about a third of their final result. At week 36 it was under 4 points, and at week 48 under 2. This is the arithmetic behind "slow is not stopped": most of the loss after week 24 arrives at a pace the trial already calls a plateau.

Why does weight loss slow down?

Because the body pushes back, and the push grows with every pound lost. The authors of the plateau analysis describe the mechanism in their paper: weight loss brings "a shift in neuroendocrine hormones that increase hunger and decrease satiety", together with changes on the spending side, such as the body using less energy than its new size alone would explain.1

A 2024 modelling study by Kevin Hall puts numbers on the idea. He fitted a mathematical model of energy balance to the average weight curves of four treatments: dieting, semaglutide 2.4 mg, tirzepatide 10 mg and gastric bypass surgery. The model has two dials. One is how hard the treatment pushes food intake down. The other is how strongly appetite climbs back as weight falls, which the paper calls the appetite feedback circuit.3

Dieting alone leaves that feedback at full strength, so appetite catches up early and the loss stops early. The model found that the two drugs and the surgery all "substantially weakened the appetite feedback control circuit, resulting in an extended period of weight loss prior to the plateau". The drug does not remove the push-back. It turns it down, so the two forces meet later and at a lower weight. The author calls these modelling results preliminary.

The model also compares the size of the push. Gastric bypass came out with a lasting effect on intake more than three times that of dieting and about double that of either drug.3 On that scale the drugs sit between a diet and surgery.

That explains the shape of every curve on this page. Loss is fastest at the start, when the drug's effect is new and little weight has gone. It slows as the lost weight raises appetite. It levels off where the two balance. The label describes the drug's side of that balance in two sentences: "Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite."2

One caution from the plateau paper itself: the trial did not measure hunger hormones or energy use, so its authors write that they "could not define which of these contribute" to the differences between people.1 The mechanism is established in general. Why one person's balance point arrives at week 24 and another's at week 60 is not.

Who plateaus earlier, and who later?

The analysis tested which features, recorded before treatment, went with a later plateau. Three stood out: a higher dose, a younger age and being female. A higher starting BMI went the same way, as the table above shows.1

Plateau by week 24Weeks 36 to 60Not by week 72
On 5 mg44%25%27%
On 10 mg32%35%33%
On 15 mg24%41%40%
Women59%76%71%
Average age46.444.643.0

Horn and colleagues, Clinical Obesity 2025, Table 2. Each column adds up to 100% across the three doses.

The dose row is the clearest. The three doses were assigned in equal numbers, so each would be about a third of every column if the dose made no difference. Among people who plateaued by week 24, 44% were on 5 mg. Among those who kept losing past week 36, 41% were on 15 mg. A lower dose brings the balance point sooner.

Women made up 59% of the early group and 76% of the later one. The age gap is small, under four years between the earliest and the latest group, but it was statistically clear. None of these features decides the matter for one person. They shift the odds.

A slow start is a different thing

An early plateau should not be confused with a slow beginning. A separate analysis of the same trial looked at people who had lost less than 5% by week 12 and called them late responders. They were 18% of the participants. By week 24, 70% of them had passed 5%, and by week 72, 90% had. The average time for a late responder to reach 5% was 24.8 weeks.4

Late responders were more often men, 45% against 30% among early responders, and were heavier at the start. So the first three months sort people one way, and the plateau sorts them another. Someone can start slowly and keep losing for a year. Someone else can start fast and level off at week 24.

At what weight does the plateau settle?

That depends mostly on the dose, and the trial gives an average for each. The label reports the loss at week 72 for everyone assigned to a dose, counting those who stopped early.2 A later report followed the participants who had prediabetes for three years.5

Average loss from starting weight5 mg10 mg15 mgPlacebo
Week 72, all participants15.0%19.5%20.9%3.1%
Week 176, participants with prediabetes12.3%18.7%19.7%1.3%

Zepbound label, Table 2, and Jastreboff and colleagues, New England Journal of Medicine 2025.

The three-year row is the best evidence there is on what a plateau looks like over time. After 176 weeks of continuous treatment the average loss was 12.3%, 18.7% and 19.7% on the three doses. Each is one to three points smaller than the loss at week 72. The two rows cover different sets of people, so they should not be subtracted exactly, but the picture is clear: the weight reached in the second year is roughly the weight held in the third. The plateau is a level, and on continued treatment it holds.

For someone who started at 231 lb, the trial's average starting weight, those three-year averages are about 203 lb on 5 mg, 188 lb on 10 mg and 185 lb on 15 mg. Individual results spread widely around them, as the plateau groups above show: the early group levelled off around 15% and the later group around 26%.

Two further trials followed people on the highest doses they tolerated. In one, people who had lost 20.9% in 36 weeks and stayed on the drug lost a further 5.5% over the next year.6 In the other, people who stayed on 10 or 15 mg were 21.9% below their starting weight at week 112.7 Both show the same slow tail after the fast phase, followed by a level.

Does a higher dose restart the loss?

No trial among the sources used here took people who had plateaued on one dose, raised it, and measured what happened. What exists is the comparison between people assigned to different doses from the start.

That comparison says the dose matters most at the low end. The average loss at week 72 was 15.0% on 5 mg and 19.5% on 10 mg, a gap of 4.5 points. From 10 mg to 15 mg the gap was 1.4 points.2 The plateau analysis adds the timing: people on the higher doses reached their plateau later and at a greater loss.1

The one trial that changed the dose in the same people went downwards. Stepping from 10 or 15 mg to 5 mg left people at a 16.6% loss a year later, against 21.9% for those who stayed on the higher dose.7 That is evidence, within one group of people, that the dose sets the level at which the weight settles.

Average loss at week 72, by assigned dose
5 mg15.0%
10 mg · 4.5 points more than 5 mg19.5%
15 mg · 1.4 points more than 10 mg20.9%

The label leaves the choice open. Its maintenance doses are 5, 10 and 15 mg, and the dose may be raised in steps of 2.5 mg after at least 4 weeks on the current one.2 So for someone whose weight has levelled off on 5 or 7.5 mg, a move up is within the label, and the group comparison suggests there is weight still to lose at a higher dose. For someone already on 15 mg there is no higher step. Whether to move is a decision for the prescriber, who will weigh it against side effects: the share of people who stopped treatment over stomach side effects rose from 1.9% on 5 mg to 4.3% on 15 mg.

The dosing schedule has each step by date and the results at each dose.

Do diet and exercise changes break a plateau?

The trial cannot show that they do, and it does show that the plateau arrives with them in place. Every participant in SURMOUNT-1, on the drug or on placebo, received lifestyle counselling for the whole trial. The label describes it as a reduced-calorie diet, with a deficit of about 500 calories a day, and at least 150 minutes of physical activity a week.2 The plateau figures on this page are the figures for people who had that support throughout.

So a plateau is not evidence that someone has stopped trying. It appeared on schedule in people who were being counselled on diet and activity throughout. That fits the mechanism: the balance point is set by appetite and energy use shifting as weight falls, and it comes whether or not a person is doing everything right.

None of the sources used here tested a specific change, such as more protein, fewer carbohydrates, a different eating window or a new exercise plan, in people who had plateaued on Zepbound. Advice of that kind is common, and it may help a given person, but it does not come from these trials. What the trials support is narrower: the counselling was part of the treatment that produced the results, so dropping it is likely to cost something.

Has the drug stopped working once the weight is flat?

No. A flat weight on Zepbound is the drug working. The clearest proof is the trial that took it away. People who had lost 20.9% in 36 weeks were split into two groups. Those who stayed on the drug lost a little more over the next year. Those switched to placebo, without knowing it, regained 14% on top of their weight, about half of everything they had lost.6

The year after week 36, in the withdrawal trial
Stayed on Zepbounda further 5.5% down
Switched to placebo14.0% up

During that year the people on the drug were, by the definition used on this page, on a plateau: 5.5% in 52 weeks is far under 5% per 12 weeks. The difference between their flat line and the rising line of the placebo group is what the drug was doing the whole time. It was holding back a regain of 14%.

This is the reason the label describes two jobs in one sentence: Zepbound is approved "to reduce excess body weight and maintain weight reduction long term".2 The first job has a natural end. The second starts where the first ends and has none. The article on what happens after stopping goes through the regain figures.

What if the weight barely moved from the start?

That is a different situation from a plateau, and the trial has numbers for it too. The label counts how many people had lost at least 5% by week 72, among everyone assigned to a dose, including those who stopped early.2

Lost by week 72Placebo5 mg10 mg15 mg
At least 5%34.5%85.1%88.9%90.9%
At least 10%18.8%68.5%78.1%83.5%
At least 15%8.8%48.0%66.6%70.6%
At least 20%3.1%30.0%50.1%56.7%

Zepbound label, Table 2, Study 1.

Read the first row from the other side: 9 to 15 in 100 people assigned to Zepbound had not lost 5% by the end of the trial. Some of them had stopped the drug. Some took it and responded little. The second row says that roughly one in six to one in three did not reach 10%.

Early weeks are a poor guide to which group a person will be in. Of the people who had lost under 5% at week 12, 70% passed 5% by week 24 and 90% by week 72.4 The authors of that analysis concluded that "extending treatment well beyond 12 weeks may allow additional patients to achieve clinically meaningful weight reduction". A small loss at three months, while the dose is still being raised, is too early to call.

The dose mattered for slow starters as it did for everyone else. The same analysis found that higher doses went with higher shares of people reaching each weight-loss threshold, both at week 24 and at week 72.4 A person who has lost little on 2.5 or 5 mg has not yet been on 10 or 15 mg, the doses at which the trial's largest losses were recorded.

What if the weight is going up while I am still on it?

The plateau analysis has little to say here, and its authors say so. They studied people whose weight stayed inside a band of 5% once it levelled off, and they note that the findings "may not be generalizable to those with greater weight variation".1

The first thing to check is the doses themselves, because the level in the body falls quickly without them. In our model, built on the label's half-life of about 5 days, the level is at 17% of its usual peak two weeks after the last injection and at 6% after three. A stretch of missed or late doses is a stretch with less drug, and the withdrawal trial shows which way weight moves then. The article on missed doses has a checker for any gap.

If the doses have been regular and the weight has risen by more than a few percent over 12 weeks, that is outside what the trials describe as a plateau, and it is the point at which to go back to the prescriber with the numbers.

Is it the same on Wegovy?

The shape is the same and the level is different. In the main Wegovy trial the average loss was 14.9% at week 68, against 2.4% on placebo, and the published curve flattens in the second half of the trial as the Zepbound curve does.8 The modelling study described above fitted semaglutide and tirzepatide with the same two dials and found the same thing for both: a weakened appetite feedback and a late plateau.3

A plateau analysis with the 5%-in-12-weeks rule has not been published for Wegovy among the sources used here, so the weeks on this page belong to Zepbound. The head-to-head comparison covers the trial that tested the two drugs against each other.

How should a plateau be measured?

The way the trial did: by comparing two weights 12 weeks apart. The trial weighed people at fixed visits, and the analysis compared each visit with the one 12 weeks before it. It did not look at week-to-week movement at all.1

For a person at home this turns into three plain steps. Weigh on the same scale, at the same time of day. Keep the weight from 12 weeks ago. Compare today with that figure, as a percentage of it. The calculator at the top does the last step.

Change over 12 weeksIn the trial's termsOur label in the calculator
Down 5% or morenot a plateaunot a plateau yet
Down 1% to under 5%plateauslow phase
Within 1% either wayplateauflat
Up 1% to under 5%plateaudrifting up
Up 5% or moreoutside the bandregain

The 5% band is the trial analysis's. The 1% lines inside it are ours, added to tell slow loss from no change.

A single 12-week comparison meets only half of the trial's rule. The other half is that every later 12-week interval also stays under 5%, and that can only be known afterwards. So the calculator can say that the last 12 weeks look like a plateau. It cannot say that the plateau has arrived for good.

What should I bring to my prescriber?

A conversation about a plateau goes better with the same numbers the trial used.

  1. Three weights. Before treatment, 12 weeks ago and now. They give the total loss and the 12-week change.
  2. The week and the dose. Week 24 on 5 mg and week 60 on 15 mg are different situations. In the first, the label has higher doses left. In the second, the trial average had levelled off too.
  3. The doses actually taken. Any missed or late injections in the last 12 weeks.
  4. Side effects at the current dose. They decide whether a higher dose is a reasonable next step.
  5. What you are aiming for. If the total loss is already near the trial average for the dose, the question shifts from losing more to holding what is lost.

What can this analysis not tell you?

It is a look back at a trial, not a test. The plateau analysis was done after the trial ended, on a question the trial was not designed for. It can show patterns. It cannot prove causes.

It left some people out. Only participants who kept to the treatment and lost at least 5% were included. People who responded little, or stopped, are not in the plateau figures.

The trial ended at week 72. For the 12 in 100 who had not levelled off by then, nobody knows when they did. The three-year follow-up covers only participants with prediabetes.

The curve values are read from a chart. The 12-week blocks on this page use the average curve in the label's Figure 3, read off the figure, and that curve shows people while on treatment. The label's table, which counts everyone, gives slightly smaller losses.

The maker paid for it. The trials and the plateau analysis were sponsored by Eli Lilly, which sells Zepbound.

Short answers to common questions

How long does a Zepbound plateau last?

On continued treatment it does not end, in the sense that matters: it is the level at which the weight stays. In the three-year follow-up the average loss at week 176 was 12.3%, 18.7% and 19.7% on 5, 10 and 15 mg, close to the levels reached in the second year.

Is a plateau at week 24 too early?

It is the most common time. About half of the people in the analysis reached theirs by week 24, at an average loss of 12.1%, and they went on to 15.4% by week 72. For people who started with a BMI under 30, the median week was 24.3.

I have not lost anything for three weeks. Is that a plateau?

Not by the trial's rule, which compares weights 12 weeks apart. Three flat weeks inside a 12-week loss of 5% or more would not count.

Will going up a dose help?

No trial has tested a dose increase in people who had plateaued. People assigned to 10 mg from the start lost 19.5% on average against 15.0% on 5 mg, and 15 mg added 1.4 points to that. The label allows increases up to 15 mg.

Does a plateau mean I should stop?

The withdrawal trial points the other way. People who stopped at a 20.9% loss regained about half of it within a year, while those who continued held their weight and lost slightly more.

Why did my friend keep losing for a year and I stopped at six months?

The analysis found later plateaus in people on higher doses, in younger people, in women and in people with a higher starting BMI. It could not explain the rest of the difference.

Is the plateau weight my new set point?

The trials do not use that term. What they show is that the level holds on continued treatment and that weight rises when the drug is stopped.

Can I still lose weight after the plateau starts?

Yes, slowly. The trial's plateau allows up to 5% per 12 weeks. The early-plateau group lost a further 3.3 points of their starting weight over the following 48 weeks.

Should I eat less when the scale stops?

The trial's counselling asked for a deficit of about 500 calories a day throughout, and the plateau arrived with that in place. No trial among the sources here tested cutting further once the weight had levelled off.

Can I tell in advance where my plateau will be?

Roughly, once the pace has dropped. The authors of the analysis write that the loss at the start of the plateau could be used to predict the longer-term result. In their data the early group added about 3 points after that and the later group about 2.

How the calculator and charts work

The calculator divides the weight you lost over the last 12 weeks by your weight 12 weeks ago. If the result is under 5% in either direction, the period meets the first part of the definition used in the trial analysis. Inside that band it uses our own lines at 1% to separate slow loss, no change and slow gain. It places you on the average curve for your dose from Figure 3 of the label and shades your last 12 weeks.

The block chart takes the same curve at weeks 0, 12, 24, 36, 48, 60 and 72 and, for each block, divides the loss in the block by the weight at its start. The dots chart rounds the three plateau groups of the analysis, 702, 567 and 169 of 1,438 people, to 49, 39 and 12 in 100. Weights in pounds for the average participant use the label's mean starting weight of about 105 kg, or 231 lb.

Sources

  1. Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1, 6.1, 12.1, 12.2 and 14.1 (Table 2, Figure 3). accessdata.fda.gov
  3. Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring) 2024;32:1163-1168. doi:10.1002/oby.24027
  4. Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025;27:5064-5071. doi:10.1111/dom.16554
  5. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392:958-971. doi:10.1056/NEJMoa2410819
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
  7. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
  8. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov

Related analyses

Log your weight each week and the app shows your 12-week change.

Open Dose Insider